A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors. Background: The initial CTC count, and the reduction in CTC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback